Last week, J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States as the Trump administration considers imposing tariffs...
J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected fourth-quarter earnings report and an optimistic outlook for the Innovative Medicine segment...
Key TakeawaysJNJ beat Q4 earnings and sales estimates, with its Innovative Medicines Unit outperforming expectations.Sales in the unit rose 4.4% YOY to $14.33 billion, led by key drugs such as Darzalex,...
Johnson & Johnson’s JNJ fourth-quarter 2024 earnings came in at $2.04 per share, which beat the Zacks Consensus Estimate of $2.00. Earnings declined 10.9% from the year-ago period. Adjusted earnings...
Key TakeawaysThe Zacks Consensus Estimate for JNJ Q4 sales and earnings is $22.5 billion and $2.01 per share, respectively.JNJ's performance has impressed, as the company exceeded earnings expectations...
For Immediate ReleaseChicago, IL – January 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks kept indexes in check
The JP Morgan Healthcare Conference, which is being held in San Francisco this year, has been much more active than last year. Among some of the top news at the conference were M&A deal announcements by...